A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-019-02315-x
Abstract: CV9201 is an RNActive®-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalation trial, 46 patients with… read more here.
Keywords: cancer; cv9201; cell; phase iia ... See more keywords